These inhibitors function by preventing the interaction between CTLA-4 and its ligands (B7-1 and B7-2), thereby eliminating the inhibitory signals on T cells, leading to enhanced anti-tumor immune responses (77, 89, 90). This evidence concerns the gene CTLA4 and neoplasm.